Click for best price

RNABased Therapeutics Vaccines Market Size, Share 2023

Market Analysis and Insights: Global RNABased Therapeutics Vaccines Market

The global RNABased Therapeutics Vaccines market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global RNABased Therapeutics Vaccines market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global RNABased Therapeutics Vaccines market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global RNABased Therapeutics Vaccines market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global RNABased Therapeutics Vaccines market.

Global RNABased Therapeutics Vaccines Scope and Market Size

RNA-Based Therapeutics and Vaccines market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global RNA-Based Therapeutics and Vaccines market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2030.

Segment by Type

RNA-Based Therapeutics

RNA-Based Vaccines

Segment by Application

Oncology

Immunology

Ophthalmology

Cardiovascular Diseases

Infectious Diseases

Genetic Diseases

Others

By Region

North America

United States

Canada

Europe

Germany

France

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

By Company

Alnylam Pharmaceuticals

Arbutus Biopharma

Arrowhead Pharmaceuticals

BioNTech

CureVac

Dicerna Pharmaceuticals

Regulus Therapeutics

Marina Biotech

MiRagen Therapeutics

Moderna Therapeutics

Quark Pharmaceuticals

Roche

Sylentis

The information for each competitor/Company Profile includes:

Company Overview
Business Strategy
Key Product Offerings
Financial Performance
Key Performance Indicators
Risk Analysis
Recent Development
Regional Presence
SWOT Analysis

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes RNABased Therapeutics Vaccines product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of RNABased Therapeutics Vaccines, with price, sales, revenue, and global market share of RNABased Therapeutics Vaccines from 2019 to 2022.

Chapter 3, the RNABased Therapeutics Vaccines competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the RNABased Therapeutics Vaccines breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the RNABased Therapeutics Vaccines market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of RNABased Therapeutics Vaccines.

Chapter 13, 14, and 15, to describe RNABased Therapeutics Vaccines sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

Estimates 2022-2027 2021-2025 RNABased Therapeutics Vaccines Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
Market dynamics scenario, along with growth opportunities of the market in the years to come
Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes	Report Details
Report Title	Global RNA-Based Therapeutics and Vaccines Market Research Report 2023
Historical Year	2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year	2022
Forecast Year	2030
Number of Pages	92 Pages
Customization Available	Yes, the report can be customized as per your need.

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global RNA-Based Therapeutics and Vaccines Market Size Growth Rate by Type: 2018 VS 2022 VS 2030
1.2.2 RNA-Based Therapeutics
1.2.3 RNA-Based Vaccines
1.3 Market by Application
1.3.1 Global RNA-Based Therapeutics and Vaccines Market Share by Application: 2018 VS 2022 VS 2030
1.3.2 Oncology
1.3.3 Immunology
1.3.4 Ophthalmology
1.3.5 Cardiovascular Diseases
1.3.6 Infectious Diseases
1.3.7 Genetic Diseases
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global RNA-Based Therapeutics and Vaccines Market Perspective (2018-2030)
2.2 RNA-Based Therapeutics and Vaccines Growth Trends by Region
2.2.1 RNA-Based Therapeutics and Vaccines Market Size by Region: 2018 VS 2022 VS 2030
2.2.2 RNA-Based Therapeutics and Vaccines Historic Market Size by Region (2018-2023)
2.2.3 RNA-Based Therapeutics and Vaccines Forecasted Market Size by Region (2023-2030)
2.3 RNA-Based Therapeutics and Vaccines Market Dynamics
2.3.1 RNA-Based Therapeutics and Vaccines Industry Trends
2.3.2 RNA-Based Therapeutics and Vaccines Market Drivers
2.3.3 RNA-Based Therapeutics and Vaccines Market Challenges
2.3.4 RNA-Based Therapeutics and Vaccines Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top RNA-Based Therapeutics and Vaccines Players by Revenue
3.1.1 Global Top RNA-Based Therapeutics and Vaccines Players by Revenue (2018-2023)
3.1.2 Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Players (2018-2023)
3.2 Global RNA-Based Therapeutics and Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by RNA-Based Therapeutics and Vaccines Revenue
3.4 Global RNA-Based Therapeutics and Vaccines Market Concentration Ratio
3.4.1 Global RNA-Based Therapeutics and Vaccines Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by RNA-Based Therapeutics and Vaccines Revenue in 2022
3.5 RNA-Based Therapeutics and Vaccines Key Players Head office and Area Served
3.6 Key Players RNA-Based Therapeutics and Vaccines Product Solution and Service
3.7 Date of Enter into RNA-Based Therapeutics and Vaccines Market
3.8 Mergers & Acquisitions, Expansion Plans
4 RNA-Based Therapeutics and Vaccines Breakdown Data by Type
4.1 Global RNA-Based Therapeutics and Vaccines Historic Market Size by Type (2018-2023)
4.2 Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Type (2023-2030)
5 RNA-Based Therapeutics and Vaccines Breakdown Data by Application
5.1 Global RNA-Based Therapeutics and Vaccines Historic Market Size by Application (2018-2023)
5.2 Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Application (2023-2030)
6 North America
6.1 North America RNA-Based Therapeutics and Vaccines Market Size (2018-2030)
6.2 North America RNA-Based Therapeutics and Vaccines Market Size by Country (2018-2023)
6.3 North America RNA-Based Therapeutics and Vaccines Market Size by Country (2023-2030)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe RNA-Based Therapeutics and Vaccines Market Size (2018-2030)
7.2 Europe RNA-Based Therapeutics and Vaccines Market Size by Country (2018-2023)
7.3 Europe RNA-Based Therapeutics and Vaccines Market Size by Country (2023-2030)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size (2018-2030)
8.2 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size by Country (2018-2023)
8.3 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size by Country (2023-2030)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America RNA-Based Therapeutics and Vaccines Market Size (2018-2030)
9.2 Latin America RNA-Based Therapeutics and Vaccines Market Size by Country (2018-2023)
9.3 Latin America RNA-Based Therapeutics and Vaccines Market Size by Country (2023-2030)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size (2018-2030)
10.2 Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size by Country (2018-2023)
10.3 Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size by Country (2023-2030)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Alnylam Pharmaceuticals
11.1.1 Alnylam Pharmaceuticals Company Detail
11.1.2 Alnylam Pharmaceuticals Business Overview
11.1.3 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
11.1.4 Alnylam Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.1.5 Alnylam Pharmaceuticals Recent Development
11.2 Arbutus Biopharma
11.2.1 Arbutus Biopharma Company Detail
11.2.2 Arbutus Biopharma Business Overview
11.2.3 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Introduction
11.2.4 Arbutus Biopharma Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.2.5 Arbutus Biopharma Recent Development
11.3 Arrowhead Pharmaceuticals
11.3.1 Arrowhead Pharmaceuticals Company Detail
11.3.2 Arrowhead Pharmaceuticals Business Overview
11.3.3 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
11.3.4 Arrowhead Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.3.5 Arrowhead Pharmaceuticals Recent Development
11.4 BioNTech
11.4.1 BioNTech Company Detail
11.4.2 BioNTech Business Overview
11.4.3 BioNTech RNA-Based Therapeutics and Vaccines Introduction
11.4.4 BioNTech Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.4.5 BioNTech Recent Development
11.5 CureVac
11.5.1 CureVac Company Detail
11.5.2 CureVac Business Overview
11.5.3 CureVac RNA-Based Therapeutics and Vaccines Introduction
11.5.4 CureVac Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.5.5 CureVac Recent Development
11.6 Dicerna Pharmaceuticals
11.6.1 Dicerna Pharmaceuticals Company Detail
11.6.2 Dicerna Pharmaceuticals Business Overview
11.6.3 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
11.6.4 Dicerna Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.6.5 Dicerna Pharmaceuticals Recent Development
11.7 Regulus Therapeutics
11.7.1 Regulus Therapeutics Company Detail
11.7.2 Regulus Therapeutics Business Overview
11.7.3 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Introduction
11.7.4 Regulus Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.7.5 Regulus Therapeutics Recent Development
11.8 Marina Biotech
11.8.1 Marina Biotech Company Detail
11.8.2 Marina Biotech Business Overview
11.8.3 Marina Biotech RNA-Based Therapeutics and Vaccines Introduction
11.8.4 Marina Biotech Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.8.5 Marina Biotech Recent Development
11.9 MiRagen Therapeutics
11.9.1 MiRagen Therapeutics Company Detail
11.9.2 MiRagen Therapeutics Business Overview
11.9.3 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Introduction
11.9.4 MiRagen Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.9.5 MiRagen Therapeutics Recent Development
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Detail
11.10.2 Moderna Therapeutics Business Overview
11.10.3 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Introduction
11.10.4 Moderna Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.10.5 Moderna Therapeutics Recent Development
11.11 Quark Pharmaceuticals
11.11.1 Quark Pharmaceuticals Company Detail
11.11.2 Quark Pharmaceuticals Business Overview
11.11.3 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
11.11.4 Quark Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.11.5 Quark Pharmaceuticals Recent Development
11.12 Roche
11.12.1 Roche Company Detail
11.12.2 Roche Business Overview
11.12.3 Roche RNA-Based Therapeutics and Vaccines Introduction
11.12.4 Roche Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.12.5 Roche Recent Development
11.13 Sylentis
11.13.1 Sylentis Company Detail
11.13.2 Sylentis Business Overview
11.13.3 Sylentis RNA-Based Therapeutics and Vaccines Introduction
11.13.4 Sylentis Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.13.5 Sylentis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global RNA-Based Therapeutics and Vaccines Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2030
Table 2. Key Players of RNA-Based Therapeutics
Table 3. Key Players of RNA-Based Vaccines
Table 4. Global RNA-Based Therapeutics and Vaccines Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2030
Table 5. Global RNA-Based Therapeutics and Vaccines Market Size by Region (US$ Million): 2018 VS 2022 VS 2030
Table 6. Global RNA-Based Therapeutics and Vaccines Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global RNA-Based Therapeutics and Vaccines Market Share by Region (2018-2023)
Table 8. Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Region (2023-2030) & (US$ Million)
Table 9. Global RNA-Based Therapeutics and Vaccines Market Share by Region (2023-2030)
Table 10. RNA-Based Therapeutics and Vaccines Market Trends
Table 11. RNA-Based Therapeutics and Vaccines Market Drivers
Table 12. RNA-Based Therapeutics and Vaccines Market Challenges
Table 13. RNA-Based Therapeutics and Vaccines Market Restraints
Table 14. Global RNA-Based Therapeutics and Vaccines Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global RNA-Based Therapeutics and Vaccines Market Share by Players (2018-2023)
Table 16. Global Top RNA-Based Therapeutics and Vaccines Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA-Based Therapeutics and Vaccines as of 2022)
Table 17. Ranking of Global Top RNA-Based Therapeutics and Vaccines Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by RNA-Based Therapeutics and Vaccines Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players RNA-Based Therapeutics and Vaccines Product Solution and Service
Table 21. Date of Enter into RNA-Based Therapeutics and Vaccines Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global RNA-Based Therapeutics and Vaccines Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Type (2018-2023)
Table 25. Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Type (2023-2030) & (US$ Million)
Table 26. Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Type (2023-2030)
Table 27. Global RNA-Based Therapeutics and Vaccines Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Application (2018-2023)
Table 29. Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Application (2023-2030) & (US$ Million)
Table 30. Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Application (2023-2030)
Table 31. North America RNA-Based Therapeutics and Vaccines Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America RNA-Based Therapeutics and Vaccines Market Size by Country (2023-2030) & (US$ Million)
Table 33. Europe RNA-Based Therapeutics and Vaccines Market Size by Country (2018-2023) & (US$ Million)
Table 34. Europe RNA-Based Therapeutics and Vaccines Market Size by Country (2023-2030) & (US$ Million)
Table 35. Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size by Region (2018-2023) & (US$ Million)
Table 36. Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size by Region (2023-2030) & (US$ Million)
Table 37. Latin America RNA-Based Therapeutics and Vaccines Market Size by Country (2018-2023) & (US$ Million)
Table 38. Latin America RNA-Based Therapeutics and Vaccines Market Size by Country (2023-2030) & (US$ Million)
Table 39. Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size by Country (2018-2023) & (US$ Million)
Table 40. Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size by Country (2023-2030) & (US$ Million)
Table 41. Alnylam Pharmaceuticals Company Detail
Table 42. Alnylam Pharmaceuticals Business Overview
Table 43. Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Product
Table 44. Alnylam Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023) & (US$ Million)
Table 45. Alnylam Pharmaceuticals Recent Development
Table 46. Arbutus Biopharma Company Detail
Table 47. Arbutus Biopharma Business Overview
Table 48. Arbutus Biopharma RNA-Based Therapeutics and Vaccines Product
Table 49. Arbutus Biopharma Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023) & (US$ Million)
Table 50. Arbutus Biopharma Recent Development
Table 51. Arrowhead Pharmaceuticals Company Detail
Table 52. Arrowhead Pharmaceuticals Business Overview
Table 53. Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Product
Table 54. Arrowhead Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023) & (US$ Million)
Table 55. Arrowhead Pharmaceuticals Recent Development
Table 56. BioNTech Company Detail
Table 57. BioNTech Business Overview
Table 58. BioNTech RNA-Based Therapeutics and Vaccines Product
Table 59. BioNTech Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023) & (US$ Million)
Table 60. BioNTech Recent Development
Table 61. CureVac Company Detail
Table 62. CureVac Business Overview
Table 63. CureVac RNA-Based Therapeutics and Vaccines Product
Table 64. CureVac Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023) & (US$ Million)
Table 65. CureVac Recent Development
Table 66. Dicerna Pharmaceuticals Company Detail
Table 67. Dicerna Pharmaceuticals Business Overview
Table 68. Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Product
Table 69. Dicerna Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023) & (US$ Million)
Table 70. Dicerna Pharmaceuticals Recent Development
Table 71. Regulus Therapeutics Company Detail
Table 72. Regulus Therapeutics Business Overview
Table 73. Regulus Therapeutics RNA-Based Therapeutics and Vaccines Product
Table 74. Regulus Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023) & (US$ Million)
Table 75. Regulus Therapeutics Recent Development
Table 76. Marina Biotech Company Detail
Table 77. Marina Biotech Business Overview
Table 78. Marina Biotech RNA-Based Therapeutics and Vaccines Product
Table 79. Marina Biotech Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023) & (US$ Million)
Table 80. Marina Biotech Recent Development
Table 81. MiRagen Therapeutics Company Detail
Table 82. MiRagen Therapeutics Business Overview
Table 83. MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Product
Table 84. MiRagen Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023) & (US$ Million)
Table 85. MiRagen Therapeutics Recent Development
Table 86. Moderna Therapeutics Company Detail
Table 87. Moderna Therapeutics Business Overview
Table 88. Moderna Therapeutics RNA-Based Therapeutics and Vaccines Product
Table 89. Moderna Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023) & (US$ Million)
Table 90. Moderna Therapeutics Recent Development
Table 91. Quark Pharmaceuticals Company Detail
Table 92. Quark Pharmaceuticals Business Overview
Table 93. Quark Pharmaceuticals RNA-Based Therapeutics and VaccinesProduct
Table 94. Quark Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023) & (US$ Million)
Table 95. Quark Pharmaceuticals Recent Development
Table 96. Roche Company Detail
Table 97. Roche Business Overview
Table 98. Roche RNA-Based Therapeutics and VaccinesProduct
Table 99. Roche Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023) & (US$ Million)
Table 100. Roche Recent Development
Table 101. Sylentis Company Detail
Table 102. Sylentis Business Overview
Table 103. Sylentis RNA-Based Therapeutics and VaccinesProduct
Table 104. Sylentis Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023) & (US$ Million)
Table 105. Sylentis Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Global RNA-Based Therapeutics and Vaccines Market Share by Type: 2022 VS 2030
Figure 2. RNA-Based Therapeutics Features
Figure 3. RNA-Based Vaccines Features
Figure 4. Global RNA-Based Therapeutics and Vaccines Market Share by Application in 2022 & 2030
Figure 5. Oncology Case Studies
Figure 6. Immunology Case Studies
Figure 7. Ophthalmology Case Studies
Figure 8. Cardiovascular Diseases Case Studies
Figure 9. Infectious Diseases Case Studies
Figure 10. Genetic Diseases Case Studies
Figure 11. Others Case Studies
Figure 12. RNA-Based Therapeutics and Vaccines Report Years Considered
Figure 13. Global RNA-Based Therapeutics and Vaccines Market Size (US$ Million), Year-over-Year: 2018-2030
Figure 14. Global RNA-Based Therapeutics and Vaccines Market Size, (US$ Million), 2018 VS 2022 VS 2030
Figure 15. Global RNA-Based Therapeutics and Vaccines Market Share by Region: 2022 VS 2030
Figure 16. Global RNA-Based Therapeutics and Vaccines Market Share by Players in 2022
Figure 17. Global Top RNA-Based Therapeutics and Vaccines Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA-Based Therapeutics and Vaccines as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by RNA-Based Therapeutics and Vaccines Revenue in 2022
Figure 19. North America RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 20. North America RNA-Based Therapeutics and Vaccines Market Share by Country (2018-2030)
Figure 21. United States RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 22. Canada RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 23. Europe RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 24. Europe RNA-Based Therapeutics and Vaccines Market Share by Country (2018-2030)
Figure 25. Germany RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 26. France RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 27. U.K. RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 28. Italy RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 29. Russia RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 30. Nordic Countries RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 31. Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 32. Asia-Pacific RNA-Based Therapeutics and Vaccines Market Share by Region (2018-2030)
Figure 33. China RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 34. Japan RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 35. South Korea RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 36. Southeast Asia RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 37. India RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 38. Australia RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 39. Latin America RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 40. Latin America RNA-Based Therapeutics and Vaccines Market Share by Country (2018-2030)
Figure 41. Mexico RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 42. Brazil RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 43. Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 44. Middle East & Africa RNA-Based Therapeutics and Vaccines Market Share by Country (2018-2030)
Figure 45. Turkey RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 46. Saudi Arabia RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 47. Alnylam Pharmaceuticals Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2018-2023)
Figure 48. Arbutus Biopharma Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2018-2023)
Figure 49. Arrowhead Pharmaceuticals Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2018-2023)
Figure 50. BioNTech Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2018-2023)
Figure 51. CureVac Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2018-2023)
Figure 52. Dicerna Pharmaceuticals Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2018-2023)
Figure 53. Regulus Therapeutics Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2018-2023)
Figure 54. Marina Biotech Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2018-2023)
Figure 55. MiRagen Therapeutics Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2018-2023)
Figure 56. Moderna Therapeutics Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2018-2023)
Figure 57. Quark Pharmaceuticals Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2018-2023)
Figure 58. Roche Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2018-2023)
Figure 59. Sylentis Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2018-2023)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed

DOWNLOAD SAMPLE

Download
Free Sample

Request
Customization

Check
Discount

REPORT PURCHASE OPTIONS

Single User Price : $2762

Multi User Price : $4143

Enterprise Price : $5524

---- OR ----

Frequently Asked Questions ?

Delivery Time

Upto 24 hrs - Working days
Upto 48 hrs max - Weekends and public holidays

User License

Single User License
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

Multi user License
A license granted to multiple users.

Site License
A license granted to a single business site/establishment.

Corporate License, Global License
A license granted to all employees within organisation access to the product.

Payment Options

Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer

Report Delivery

Email
Hard Copy

Our Key Features

Data Accuracy and Reliability
Data Security
Customized Research
Trustworthy
Competitive Offerings

Global RNA-Based Therapeutics and Vaccines Market Research Report 2023